Hyloris Pharmaceuticals (FRA:52U) Stock Based Compensation: €0.67 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:52U Hyloris Pharmaceuticals SA FRA:52U
71 GF Score
Price €4.54
GF Value €8.39
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Hyloris Pharmaceuticals Stock Based Compensation?

Hyloris Pharmaceuticals FRA:52U +2.02% 71 Stock Based Compensation is €0.67 Mil as of Dec. 2025. GuruFocus rates FRA:52U with a GF Score™ of 71/100 and a GF Value™ of €8.39 (Possible Value Trap). The stock has 3 warning signs investors should review.

Hyloris Pharmaceuticals's Stock Based Compensation for the six months ended in Dec. 2025 was €0.36 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was €0.67 Mil.

Hyloris Pharmaceuticals Stock Based Compensation Related Terms

Hyloris Pharmaceuticals Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Hyloris Pharmaceuticals's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hyloris Pharmaceuticals Stock Based Compensation Chart

Hyloris Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.58 0.56 0.54 -0.58 0.67

Hyloris Pharmaceuticals Semi-Annual Data
Dec16 Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 -0.92 0.34 0.30 0.36
FRA:52U
71GF Score
Hyloris Pharmaceuticals SA FRA:52U
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hyloris Pharmaceuticals Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.67 Mil.

What does a Stock Based Compensation of €0.67 Mil mean?
Hyloris Pharmaceuticals (FRA:52U) has a Stock Based Compensation of €0.67 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Hyloris Pharmaceuticals and its competitors.
Is Hyloris Pharmaceuticals' Stock Based Compensation too high?
Hyloris Pharmaceuticals' current Stock Based Compensation is €0.67 Mil. Overall, Hyloris Pharmaceuticals has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hyloris Pharmaceuticals' Stock Based Compensation compare to VRTX and REGN?
Hyloris Pharmaceuticals' Stock Based Compensation of €0.67 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Hyloris Pharmaceuticals and its competitors. Hyloris Pharmaceuticals's current Stock Based Compensation is €0.67 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hyloris Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hyloris Pharmaceuticals (FRA:52U) is currently considered Possible Value Trap. The stock's GF Value™ is €8.39, compared to a current price of €4.54 — trading 45.9% below its estimated fair value. The current Stock Based Compensation is €0.67 Mil. Hyloris Pharmaceuticals' overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Hyloris Pharmaceuticals (FRA:52U), the current Stock Based Compensation is €0.67 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hyloris Pharmaceuticals (FRA:52U) Overvalued in 2026?

Based on GuruFocus' analysis, Hyloris Pharmaceuticals stock appears to be undervalued. The current stock price of €4.54 is trading 45.9% below its estimated GF Value™ of €8.39. GuruFocus considers Hyloris Pharmaceuticals to be Possible Value Trap.

Key valuation signals for FRA:52U:

  • Stock Based Compensation: €0.67 Mil
  • GF Value™: €8.39 vs. price of €4.54 (45.9% below fair value)
  • GF Score™: 71/100 with 3 warning signs

No single metric tells the full story. See the FRA:52U stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hyloris Pharmaceuticals Business Description

Other Exchanges 0AB6:UKHYL:Belgium
Address Boulevard Patience et Beaujonc No. 3/1, Liege, BEL, 4000
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has three early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, Podofilox Ge, and Maxigesic IV. Its revenue is mainly generated in the United States.
71GF Score

Get the complete analysis for FRA:52U

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.54
Price
€8.39
GF Value